Tilray stock rises 29% on plans to import cannabis to U.S. for clinical trial

Charlotte ObserverTilray stock rises 10% on plans to import cannabis to US for clinical trialMarketWatchThe U.S. Drug Enforcement Administratio.....»»

The U.S. Drug Enforcement Administration has signed off on cannabis cultivator Tilray Inc.’s plan to import a pot product from Canada to test a pot pill’s effectiveness at treating a disorder that affects millions of Americans......»»

The U.S. Drug Enforcement Administration has signed off on cannabis cultivator Tilray Inc.’s plan to import a pot product from Canada to test a pot pill’s effectiveness at treating a disorder that affects millions of Americans......»»

U.S. Rep. Matt Gaetz, a Florida Republican who is spearheading a medical cannabis reform law, has questioned this week’s decision to allow Canada-based Tilray Inc. to import the drug for use in a clinical trial......»»

Cannabis stocks are having a better day today than they did yesterday, but Til.....»»

Shares of Precision BioSciences Inc. are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell therapy.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Tilray, Inc. (NASDAQ: TLRY) announced Thursday it has imported medical cannabis into the U.S. from Canada to back a new clinical trial. read more.....»»

Tilray Inc. shares rose 5% in the extended session Tuesday after the Canadian weed maker topped consensus revenue estimates by nearly tripling sales, but lost more money than analysts expected......»»

Tilray Inc. finally showed investors that it is capable of selling recreational pot in Canada......»»

Tilray Inc. shares gained more than 4% in the extended session Monday af.....»»

Tilray received approval to .....»»

Tilray Inc. became the first cannabis company to go public on the Nasdaq this year, marking an important turning point for the sector — the successful IPO, Chief Executive Brendan Kennedy told MarketWatch, was a validation for the overall industry......»»

Pfizer Inc (NYSE: PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. read more.....»»

Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth c.....»»

Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the co.....»»

Aurora Cannabis Inc. reported another large quarterly loss Thursday, and announced more cost-cutting, share-sale plans and executive changes as shares plunged in late trading......»»

Shares of Inovio Pharmaceuticals Inc. gained 8.0% in premarket trading on Monday after the company said its experimental COVID-19 vaccine was safe and also triggered antibody titers in 400 or so adult participants in a P.....»»

Shares of ODP Corp. were indicated up more than 2% in premarket trading Wednesday, after the office supply retailer announced plans to separate into two independent, publicly traded companies. The separation is expected to occur through a distributio.....»»

Canadian cannabis company Tilray Inc. said Monday its shares will continue to trade on Nasdaq under the ticker symbol "TLRY" after its merger with fellow Canadian cannabis company Aphr.....»»